Form 4 for CRSP CRISPR Therapeutics AG
Accepted 2024-02-16 00:00:00 ET · period of report 2024-02-15 · accession 0000950170-24-016574 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-02-16 | 2024-02-15 | CRSP | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $80.36 | -20.0K | 194.4K | -9% | -$1.61M |
| DT | 2024-02-16 | 2024-02-15 | CRSP | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +20.0K | 207.4K | +11% | +$382.4K |
| DT | 2024-02-16 | 2024-02-15 | CRSP | Kulkarni Samarth | CEO, Dir | M - OptEx | $0.00 | -20.0K | 39.6K | -34% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-02-15 | S | D | 1,100 | $81.66 | 187,377 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.55 to $81.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 2 | Common | Common Shares | 2024-02-15 | S | D | 5,951 | $81.04 | 188,477 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.55 to $81.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Common | Common Shares | 2024-02-15 | M | A | 20,000 | $19.12 | 207,377 | D | — | — | |
| 4 | Common | Common Shares | 2024-02-15 | S | D | 12,949 | $79.94 | 194,428 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.40 to $80.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-02-15 | M | D | 20,000 | $0.00 | 39,582 | D | $19.12 · — to 2027-12-01 | 20,000 Common Shares | (F5) This option was granted on December 1, 2017 with respect to 260,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning January 1, 2018. |